Novartis’ BYL719 Improved Patient Survival in Phase 3 Trial of Advanced Breast Cancer
News
Treatment with Novartis’s BYL719 (alpelisib) was seen to improve progression-free survival (PFS) in the Phase 3 SOLAR-1 clinical trial in patients with HR-positive, HER2-negative advanced breast cancer who received prior ... Read more